Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Compared with the AFF group treated with AR, patients in the control group, i.e., with hip fractures on BPs therapy, were slightly older (P = 0.026), had lower BMI (P = 0.011), a trend for shorter AR duration (P = 0.071), and higher CTX levels (P = 0.002).Patient characteristics according to the use of antiresorptive drugsAFF groupP valueaHip fracture groupP valuebTotal n = 72No antiresorptive drug use n = 10Antiresorptive drug users n = 62Antiresorptive drug users n = 20nMedian (IQR) or %nMedian (IQR) or %nMedian (IQR) or %nMedian (IQR) or %Age (years)7277 (16)1077 (22)6277 (15)0.7752082 (13)0.026Sex (female, %)7290%1090%6290%0.9752090%0.966BMI (kg/m2)6624.3 (5.8)829.2 (7.4)5824.0 (5.4)0.0171621.2 (3.0)0.011Fractures characteristics Bilateral AFF (%)7229%1010%6232%0.151NANANA Bilateral simultaneous AFF (%)2176%1100%2075%0.567NANANA Metatarsal fracture (%)7214%100%6216%0.171NANANA Pertrochanteric fracture, (%)NANANANANANANANA13 (65%)NA Femoral neck fracture, (%)NANANANANANANANA7 (35%)NA Lowest ALP values (IU/L)7258 (46)1086 (40)6256 (39)0.0402053 (16)0.313 ALP ≤ 40 IU/L7225%100%6229%0.0492020%0.428 Patients on AR therapy, (%)7286%100%62100% < 0.00120100%NA Type of AR therapy72A, I, Z, D, P10062A, I, Z, D, PNA20A, I, Z, DNA Duration of AR (years)706 (8)100 (0)608 (6) < 0.001194 (7)0.071 Osteoporosis (%)c5645%617%5048%0.145NANANACorticosteroid users (%)d7111%1010%6111%0.891NANANA PPI users (%)7249%1050%6248%0.925NANANA 25-OH Vitamin D (nmol/L)4560 (33)258 (100)60 (33)0.9560NANA CTX (ng/mL)37273 (224)11058 (0)36270 (216)0.11113442 (250)0.002A alendronate, AFF atypical femur fracture, BMI body mass index, ALP alkaline phosphatase, D denosumab, I ibandronate, P pamidronate, PPI proton pump inhibitors, NA not applicableaAFF with versus AFF without antiresorptive drug usebHip fracture group vs AFF with antiresorptive drug usecOsteoporosis defined as at least one T-score ≤: 2.5 SD at the lumbar spine, total hip, or femoral neckdRange of prednisone dose, 2 to 30 mg/dayP-values in bold < 0.05 are considered statistically significant
Source: Patient Characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
In the AFF cohort 72 patients aged 18 years or older, who were diagnosed with AFF and hospitalized at the Service of Orthopedics at the Geneva University Hospitals between 2000 and 2020 were included.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Prevalence of Low Serum Alkaline Phosphatase and Hypophosphatasia in Adult Patients with Atypical Femur Fractures
Study design awaiting verification · Calcified Tissue International · 2022
Original publication title
Prevalence of Low Serum Alkaline Phosphatase and Hypophosphatasia in Adult Patients with Atypical Femur Fractures
© The Author(s) 2022
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Hypophosphatasia (HPP) is a rare genetic disorder characterized by low serum alkaline phosphatase (ALP), its manifestations may include atypical femoral fractures (AFF). However, the prevalence of low serum ALP and HPP in patients with AFF remains unknown. We retrospectively analyzed ALP levels and clinical manifestations compatible with HPP in 72 adult patients with confirmed AFF by chart review. ALP values were compared with those of a control group of patients with prior proximal femoral fracture during antiresorptive treatment (n = 20).
Among the AFF patients, 18 (25%) had at least one serum ALP value ≤ 40 IU/L, although in all but one case, at least one ALP value > 40 IU/L was also detected at another time point. Most low ALP values were associated with antiresorptive treatment (P = 0.049) and lowest levels of ALP did not differ between the AFF and the control groups (P = 0.129). However, low ALP values among AFF patients were associated with a higher rate of bilateral AFF (50% vs 22%, P = 0.025), metatarsal fracture (33% vs 7%, P = 0.006), and with trends for more frequent use of glucocorticoid (22% vs 8%, P = 0.089) and proton pump inhibitor (61% vs 44%, P = 0.220).
In one AFF patient with low ALP and clinical suspicion of HPP, a rare pathogenic heterozygous variant of the ALPL gene was identified. In conclusion, low ALP values are common among subjects with AFF and mainly related to concomitant antiresorptive medication. Hence, low serum ALP has low specificity for HPP among AFF patients.
Authors’ abstract
Hypophosphatasia (HPP) is a rare genetic disorder characterized by low serum alkaline phosphatase (ALP), its manifestations may include atypical femoral fractures (AFF). However, the prevalence of low serum ALP and HPP in patients with AFF remains unknown. We retrospectively analyzed ALP levels and clinical manifestations compatible with HPP in 72 adult patients with confirmed AFF by chart review. ALP values were compared with those of a control group of patients with prior proximal femoral fracture during antiresorptive treatment (n = 20).
Among the AFF patients, 18 (25%) had at least one serum ALP value ≤ 40 IU/L, although in all but one case, at least one ALP value > 40 IU/L was also detected at another time point. Most low ALP values were associated with antiresorptive treatment (P = 0.049) and lowest levels of ALP did not differ between the AFF and the control groups (P = 0.129). However, low ALP values among AFF patients were associated with a higher rate of bilateral AFF (50% vs 22%, P = 0.025), metatarsal fracture (33% vs 7%, P = 0.006), and with trends for more frequent use of glucocorticoid (22% vs 8%, P = 0.089) and proton pump inhibitor (61% vs 44%, P = 0.220).
In one AFF patient with low ALP and clinical suspicion of HPP, a rare pathogenic heterozygous variant of the ALPL gene was identified. In conclusion, low ALP values are common among subjects with AFF and mainly related to concomitant antiresorptive medication. Hence, low serum ALP has low specificity for HPP among AFF patients.
Publication and source details
Original title: Prevalence of Low Serum Alkaline Phosphatase and Hypophosphatasia in Adult Patients with Atypical Femur Fractures
Eleni Tsiantouli; Emmanuel Biver; Thierry Chevalley; Robert Petrovic; Didier Hannouche; Serge Ferrari
Calcified Tissue International · 2022
© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.University of GenevaOpen access funding provided by University of Geneva
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T10:08:47.533693+00:00
DOI: 10.1007/s00223-022-00949-1 · PMC9108106